Navigation Links
Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
Date:2/22/2013

NEW YORK, Feb. 22, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the Citigroup 2013 Global Healthcare Conference, being held February 25-27, 2013, in New York City.  Mr. Bentsur's presentation is scheduled to take place on Wednesday, February 27th, at 2:15 PM ET. 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in <
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
8. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
9. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Calif. , May 22, 2015 /PRNewswire/ ... the Company has commenced termination of its ... brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE: ... inhibitor, is in development for patients with ... spondyloarthritis.  The decision was based on events ...
(Date:5/22/2015)... ORLANDO, Fla. , May 22, 2015 ... Copay Assistance Program. This program provides financial assistance for ... "We are pleased to announce the addition of the ... programs," stated Mark McGreevy , executive director. "With ... mission and vision of a world where no one ...
(Date:5/22/2015)... 2015  The U.S. Food and Drug Administration,s ... first biosimilar product approved in the ... in the contract manufacturing organization (CMO) industry, according ... geared to the production of small-molecular drugs and ... The healthcare market research publisher,s report, Biopharmaceutical ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... Inc. (Nasdaq: MSON ), a developer of minimally ... used for the ablation of tumors and worldwide for ... first quarter ended September 30, 2009 financial results on ... President and Chief Executive Officer and Richard Zaremba, Senior ...
... Ind., Nov. 12 Zimmer Holdings, Inc. (NYSE: ZMH ... sell $1.0 billion of its senior unsecured notes in an ... due 2019 and $500.0 million of 5.75% notes due 2039. ... above their Treasury benchmark, and the 30-year notes were priced ...
Cached Medicine Technology:Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern 2Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2
(Date:5/22/2015)... (PRWEB) May 22, 2015 Family, friends, ... Hospital’s world-renowned surgical oncologist, Dr. LaSalle D. Leffall, on ... The luncheon began after Grand Rounds in the hospital’s ... waited anxiously outside the auditorium, trying to keep the ... but if he sees me, he’ll know something is ...
(Date:5/22/2015)... R.I. (PRWEB) May 22, 2015 Memorial Day ... Amica Insurance is offering some tips to help ... Safety Council, there will be 383 traffic fatalities this Memorial ... from the National Highway Traffic Safety Association: , ... in the vehicle is wearing a seatbelt, whether they’re driving ...
(Date:5/22/2015)... 2015 Coco Libre, the Official Coconut Water ... Record at the 104th running of the race. On Sunday, ... served 315 people in one hour—one person about every 10 ... so true to the heart of the Bay Area, so ... luge to the finish line only made sense,” said Jennifer ...
(Date:5/22/2015)... West Hollywood, CA (PRWEB) May 22, 2015 ... at Sunset Plaza Dental announces that they ... in cosmetic, restorative and other dental treatments. At ... that interest them. Questions regarding what certain treatments ... can also be covered during this initial appointment. ...
(Date:5/22/2015)... sweetFrog Enterprises, LLC. is pleased to announce the ... now the 16th sweetFrog store located in the Lone Star ... on the Inc. 500 list of fastest growing companies in ... East Texas for 20 years and love the natural beauty ... and nearby Palestine, sweetFrog locations. “We are really excited about ...
Breaking Medicine News(10 mins):Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
... By Serena Gordon HealthDay Reporter , FRIDAY, ... helped prevent or slow the progression of type 1 diabetes ... too early to say if the results might apply to ... the immune system,s response to newly developing diabetes, and reduced ...
... HealthDay Reporter , FRIDAY, May 11 (HealthDay News) ... health, reducing stress levels and contributing to better focus, a ... Irvine, and the U.S. Army found that a group of ... five days experienced more natural, variable heart rates and switched ...
... a concentrated, highly targeted dose of radiation to the ... area, with no adverse effects on survival and a ... the ten-year results of a randomised trial, Professor Csaba ... Institute of Oncology, Budapest, will tell the World Congress ...
... KU Leuven, succeeded in undoing the effect of one ... vitamin K2. His discovery gives hope to Parkinson,s patients. ... Northern Illinois University (US) and will be published this ... Science ., "It appears from our research that administering ...
... Denise Mann HealthDay Reporter , THURSDAY, May 10 ... marrow stem cells to enhance their healing potential may help ... small study suggests. Researchers developed the treatment by ... process helped increase the amount of immune cells and stem ...
... Inducing labor after a woman has been pregnant for more ... before, during or shortly after birth without increasing the need ... born after induced labor were also more likely to require ... led by Sarah Stock of the School of Women and ...
Cached Medicine News:Health News:Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says 2Health News:Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says 3Health News:'Email Vacations' Boost Job Productivity, Lower Stress: Study 2Health News:'Email Vacations' Boost Job Productivity, Lower Stress: Study 3Health News:Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer 2Health News:Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer 3Health News:Vitamin K2: New hope for Parkinson's patients? 2Health News:Stem Cell Study Shows Promising Results Against Heart Failure 2Health News:Stem Cell Study Shows Promising Results Against Heart Failure 3Health News:Induced Labor Late in Pregnancy Has Pros, Cons 2
This is an economical (portable) microtome designed for fast and accurate sectioning. The specimen rise is automatic and accurate with each handle movement. Section thickness from 5 to 40 microns. ...
Disposable Feather Blades, 50 per pack...
Fine abrasive for knife sharpening, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Medicine Products: